However, in order to optimize 131I therapy for treatment of radioiodine sensitive differentiated thyroid cancers and to discover NIS-inducing drugs for radioiodine refractory cancer, it is essential to develop an athyroid animal model of thyroid cancer. Here, SLC5A5 is linked to thyroid gland carcinoma.